CHINARES PHARMA (03320): KPC Pharmaceuticals, Inc. net loss of approximately RMB 363 million for the first 9 months, turning from profit to loss year-on-year
CHINARES PHARMA (03320) announced the results of KPC Pharmaceuticals, Inc. for the first 9 months of 2026, with total operating revenue of approximately RMB 2.722 billion, a year-on-year decrease of 42.7%; net loss of approximately RMB 363 million, turning from profit to loss year-on-year.
CHINARES PHARMA (03320) announced the results of KPC Pharmaceuticals, Inc. for the first 9 months of 2026, with total operating revenue of approximately RMB 2.722 billion, a year-on-year decrease of 42.7%; net loss of approximately RMB 363 million, turning from profit to loss year-on-year.
Related Articles
Shenzhen Zhaowei Machinery & Electronics (02692) Responds to A-share Stock Price Anomaly: Humanoid Siasun Robot&Automation-Related Revenue Accounts for a Very Low Proportion, No Large New Orders at Present
CH INV FIN GP (01226): Elite Partners CPA Limited Resigns as Auditor of the Company
MAXICITY (02295): Wu Kunmin Appointed as Executive Director, Chief Executive Officer and Chairman of the Board
Shenzhen Zhaowei Machinery & Electronics (02692) Responds to A-share Stock Price Anomaly: Humanoid Siasun Robot&Automation-Related Revenue Accounts for a Very Low Proportion, No Large New Orders at Present
CH INV FIN GP (01226): Elite Partners CPA Limited Resigns as Auditor of the Company
MAXICITY (02295): Wu Kunmin Appointed as Executive Director, Chief Executive Officer and Chairman of the Board
